ABECMA generated $ 72M U.S. commercial revenue in 2Q; continues to track toward upper end of $250-$300M revenue guidance for 2022 Results from prespecified interim analysis of KarMMa-3 trial shows ABECMA (idecabtagene vicleucel) significantly improves progression-free survival versus standard
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 3, 2022-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences: 2022 Wedbush PacGrow Healthcare Conference , “A View to a Kill(er Cell) – Part 1” panel on
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 6, 2022-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that it will participate in a fireside chat at the Goldman Sachs 43 rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 14, 2022 at 3:20pm PT .
First patients enrolled in clinical studies in bNHL and AML ABECMA generated $56M U.S. commercial revenue in 1Q; continues to track toward upper end of $250-$300M U.S. ABECMA revenue guidance for 2022 Ended quarter with $452.5M cash, cash equivalents, and marketable securities; anticipated cash
bbT369, 2seventy bio’s investigational novel CD79a/CD20 dual targeting CBLB gene edited CAR T cell therapy demonstrates promising anti-lymphoma activity in preclinical models bbT369 is the first novel cell therapy investigated in the clinic that uses 2seventy bio’s proprietary highly specific
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 7, 2022-- 2seventy bio, Inc . (Nasdaq: TSVT) announced today that it will present at the CG Horizons in Oncology Virtual Conference , on the Attacking AML: New Approaches Panel on Thursday, April 14, 2022 at 1:30pm ET .
Closed $170M private placement with leading healthcare investors ABECMA generated $158M U.S. commercial revenue in 2021; tracking toward upper end of $250-300M U.S. revenue guidance for 2022 Internal cost reduction measures reduce net cash spend guidance to $190-220M for 2022 Cash runway into
Proceeds to support 2seventy bio’s pipeline of novel cell therapy programs Financing, combined with reduced net cash spend and ABECMA commercial progress, supports extension of cash runway into 2025 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2022-- 2seventy bio, Inc .
Steven Bernstein , M.D. appointed to chief medical officer Susan Abu-Absi , Ph.D. promoted to chief technology & manufacturing officer CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 14, 2022-- 2seventy bio, Inc . (NASDAQ: TSVT) announced that Steven Bernstein , M.D.
